Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag UniQure's gene therapy for a specific ALS type gets safety nod, plans more patient trials.

flag UniQure, a gene therapy company, received a positive safety review for its AMT-162 treatment for a specific type of ALS from an independent committee. flag The therapy targets ALS caused by mutations in the SOD1 gene. flag The company plans to enroll more patients in the first quarter of 2025 to further test the safety and potential effectiveness of the treatment.

3 Articles

Further Reading